ArticleOncotarget2018
Adenosine A
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- Overexpression of adenosine receptor (A1, A2a, A2b, A3) genes in esophageal tumor tissue: A2b adenosine receptor as a potential biomarker and anticancer target.Journal of applied genetics · 2026Article
- First-in-human study of the dual AESMO open · 2026Article
- Dual blockade of adenosine AFrontiers in immunology · 2026Article
- Oncostatin M upregulates CD73 via the MAPK pathway in keratinocytes to promote an adenosine-dependent anti-inflammatory response in psoriasis.Frontiers in immunology · 2026Article
- Cannabinoid CBACS pharmacology & translational science · 2025Article
- Mitochondrial Localization and Function of Adenosine Receptors.International journal of biological sciences · 2025Article
- Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation.Frontiers in immunology · 2025Review
- Caffeine Inhibits Both Basal and Insulin-Activated Urate Transport.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Comprehensive Review on Bimolecular Fluorescence Complementation and Its Application in Deciphering Protein-Protein Interactions in Cell Signaling Pathways.Biomolecules · 2024Review
- The Expression and Functionality of CBInternational journal of molecular sciences · 2024Article
- Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective.Molecular neurobiology · 2023Review
- IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling.The Journal of clinical investigation · 2023Article
- The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer.International journal of molecular sciences · 2023Review
- Exploring the Effect of Halogenation in a Series of Potent and Selective AJournal of medicinal chemistry · 2023Article
- Impact of the selective A2British journal of cancer · 2022Article
- Review
- Adenosine ABritish journal of pharmacology · 2022Review
- AJournal for immunotherapy of cancer · 2022Article
- Expression of the Adenosine ABiomedicines · 2022Article
- Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adenosine receptor (AR) subtypes A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.